Triptorelin

Generic Name: Triptorelin

Brand Names: Decapeptyl, Trelstar, Triptodur

Drug Type: Small Molecule

Chemical Formula: C_₆₄H_₈₂N_₁₈O_₁₃

CAS Number: 57773-63-4

Unique Ingredient Identifier: 9081Y98W2V

Background: Triptorelin is a synthetic decapeptide agonist analog of luteinizing hormone releasing hormone (LHRH). Possessing greater potency than endogenous LHRH, triptorelin reversibly represses gonadotropin secretion. After chronic, continuous administration, this agent effects sustained decreases in LH and FSH production and testicular and ovarian steroidogenesis. Serum testosterone concentrations may fall to levels typically observed in surgically castrated men.

Indication: Triptorelin is indicated for the palliative treatment of advanced prostate cancer.

Associated Conditions: Advanced Prostate Cancer

Associated Therapies: Controlled ovarian hyperstimulation therapy

Clinical Trials

Testing the Addition of Darolutamide to Hormonal Therapy (Androgen Deprivation Therapy [ADT]) After Surgery for Men With High-Risk Prostate Cancer, The ERADICATE Study

Phase 3

Active, not recruiting

Conditions: Prostate Carcinoma

Interventions: Drug: Goserelin Acetate
Drug: Darolutamide
Drug: Leuprolide Acetate
Drug: Placebo Administration
Other: Quality-of-Life Assessment
Drug: Triptorelin

First Posted Date: 2020-07-24

Last Posted Date: 2025-01-28

Lead Sponsor: ECOG-ACRIN Cancer Research Group

Target Recruit Count: 27

Registration Number: NCT04484818

Locations: 🇺🇸
Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States
🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸
Los Angeles County-USC Medical Center, Los Angeles, California, United States

and more 112 locations

Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging

Phase 3

Recruiting

Conditions: Biochemically Recurrent Prostate Carcinoma
Stage IVB Prostate Cancer AJCC v8
Metastatic Prostate Carcinoma
Prostate Adenocarcinoma

Interventions: Procedure: Computed Tomography
Radiation: 3-Dimensional Conformal Radiation Therapy
Drug: Apalutamide
Drug: Degarelix
Radiation: External Beam Radiation Therapy
Other: Fluciclovine F18
Drug: Goserelin Acetate
Drug: Leuprolide Acetate
Procedure: Magnetic Resonance Imaging
Procedure: Positron Emission Tomography
Procedure: Intensity-Modulated Proton Therapy
Other: Quality-of-Life Assessment
Radiation: Intensity-Modulated Radiation Therapy
Other: Questionnaire Administration
Drug: Relugolix
Drug: Triptorelin
Radiation: Stereotactic Body Radiation Therapy
Radiation: Volume Modulated Arc Therapy

First Posted Date: 2020-06-09

Last Posted Date: 2024-11-05

Lead Sponsor: ECOG-ACRIN Cancer Research Group

Target Recruit Count: 804

Registration Number: NCT04423211

Locations: 🇺🇸
Rush University Medical Center, Chicago, Illinois, United States
🇺🇸
Anchorage Associates in Radiation Medicine, Anchorage, Alaska, United States
🇺🇸
Alaska Breast Care and Surgery LLC, Anchorage, Alaska, United States

and more 299 locations

Androgen Deprivation Therapy on Bone Mineral Density Change in Prostate Cancer Patients

Phase 4

Conditions: Prostatic Neoplasms

Interventions: Drug: Leuprorelin
Drug: Goserelin
Drug: Triptorelin
Drug: Degarelix
Drug: Bicalutamide
Drug: Flutamide
Drug: Maximum androgen blockade

First Posted Date: 2020-01-30

Last Posted Date: 2021-07-29

Lead Sponsor: Wonju Severance Christian Hospital

Target Recruit Count: 164

Registration Number: NCT04248621

Locations: 🇰🇷
Department of Urology, Chonnam National University, School of Medicine, Gwangju, Korea, Republic of
🇰🇷
Department of Urology, Kyungpook National University, School of Medicine, Daegu, Korea, Republic of
🇰🇷
Department of Urology, Eulji University, College of Medicine, Daejeon, Korea, Republic of

and more 7 locations

Long-term Better Than Short-term ADT With Salvage RT

Phase 2

Recruiting

Conditions: Prostate Cancer

Interventions: Drug: Triptoreline

First Posted Date: 2020-01-27

Last Posted Date: 2023-12-13

Lead Sponsor: Universitaire Ziekenhuizen KU Leuven

Target Recruit Count: 394

Registration Number: NCT04242017

Locations: 🇧🇪
UZ Gent, Gent, Belgium
🇧🇪
UZ Leuven, Leuven, Belgium
🇧🇪
AZ Maria Middelares, Gent, Belgium

Generation of Biological Samples Positive to Triptorelin for Anti-doping Control

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Triptorelin

First Posted Date: 2019-12-06

Last Posted Date: 2019-12-11

Lead Sponsor: Parc de Salut Mar

Target Recruit Count: 2

Registration Number: NCT04189900

Locations: 🇪🇸
IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain

Luteal Phase Support In IVF Women Using GnRH Agonist

Completed

Conditions: IVF
Luteal Phase Defect

Interventions: Drug: Decapeptyl 0.2mg

First Posted Date: 2019-11-22

Last Posted Date: 2019-11-25

Lead Sponsor: National University of Malaysia

Target Recruit Count: 222

Registration Number: NCT04174378

Locations: 🇲🇾
Medically Assisted Conception Unit, UKM Medical Centre, Cheras, Kuala Lumpur, Malaysia

Comparative Study on the Efficacy of Ovarian Stimulation Protocols on the Success Rate of ICSI in Female Infertility

Phase 1

Completed

Conditions: Female Infertility
Female Infertility Due to Ovulatory Disorder
Female Infertility of Tubal Origin
Premature Ovarian Failure
Polycystic Ovary Syndrome
Ectopic Pregnancy
Salpingitis
Female Infertility Due to Tubal Block
Female Infertility Due to Tubal Occlusion
Hydrosalpinx

Interventions: Drug: Human Chorionic Gonadotropin (hCG)
Drug: Gonadotropins
Drug: GNRH-A Triptorelin
Drug: GnRH antagonist

First Posted Date: 2019-08-28

Last Posted Date: 2023-05-09

Lead Sponsor: Lebanese University

Target Recruit Count: 200

Registration Number: NCT04071574

Locations: 🇱🇧
Lebanese University, faculty of sciences III, Tripoli, North Lebanon, Lebanon

Radiotherapy Combined With a LHRH (Ant)Agonist Versus Apalutamide in Patients With Biochemical Recurrence After RP

Phase 2

Recruiting

Conditions: Cancer of Prostate

Interventions: Drug: Leuprorelin Acetate 45Mg Powder for Injection Suspension Vial
Drug: Apalutamide
Drug: Goserelin Acetate 10.8 MG Subcutaneous Implant
Drug: Triptorelin Pamoate
Drug: Degarelix acetate

First Posted Date: 2019-04-02

Last Posted Date: 2024-02-07

Lead Sponsor: Cancer Research Antwerp

Target Recruit Count: 202

Registration Number: NCT03899077

Locations: 🇧🇪
AZ Sint-Jan, Brugge, Belgium
🇧🇪
OLVZ Aalst, Aalst, Belgium
🇧🇪
CH Jolimont, Haine-Saint-Paul, Belgium

and more 6 locations

The Effectiveness and Safety of the Prolonged Down-regulation Protocol for Controlled Ovarian Hyperstimulation

Phase 4

Conditions: Infertility, Female

Interventions: Drug: Triptorelin acetate

First Posted Date: 2019-01-18

Last Posted Date: 2019-01-18

Lead Sponsor: Peking University People's Hospital

Target Recruit Count: 1892

Registration Number: NCT03809221

Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer

Phase 3

Recruiting

Conditions: Castration Levels of Testosterone
Metastatic Prostatic Adenocarcinoma
Stage IV Prostate Cancer AJCC v8
Stage IVA Prostate Cancer AJCC v8
Stage IVB Prostate Cancer AJCC v8

Interventions: Drug: Abiraterone
Drug: Bicalutamide
Drug: Degarelix
Drug: Flutamide
Drug: Docetaxel
Drug: Goserelin Acetate
Drug: Histrelin Acetate
Drug: Leuprolide Acetate
Drug: Nilutamide
Procedure: Orchiectomy
Other: Quality-of-Life Assessment
Radiation: Radiation Therapy
Drug: Prednisone
Procedure: Radical Prostatectomy
Drug: Triptorelin

First Posted Date: 2018-09-19

Last Posted Date: 2024-08-16

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 1273

Registration Number: NCT03678025

Locations: 🇺🇸
USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸
Parkland Memorial Hospital, Dallas, Texas, United States
🇺🇸
UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas, United States

and more 335 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy